NO329021B1 - Anvendelse av escitalopram for behandling av generell angstforstyrrelse - Google Patents
Anvendelse av escitalopram for behandling av generell angstforstyrrelse Download PDFInfo
- Publication number
- NO329021B1 NO329021B1 NO20020062A NO20020062A NO329021B1 NO 329021 B1 NO329021 B1 NO 329021B1 NO 20020062 A NO20020062 A NO 20020062A NO 20020062 A NO20020062 A NO 20020062A NO 329021 B1 NO329021 B1 NO 329021B1
- Authority
- NO
- Norway
- Prior art keywords
- test
- escitalopram
- treatment
- day
- anxiety disorder
- Prior art date
Links
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 title claims description 15
- 229960004341 escitalopram Drugs 0.000 title claims description 14
- 238000011282 treatment Methods 0.000 title claims description 14
- 208000011688 Generalised anxiety disease Diseases 0.000 title claims description 9
- 208000029364 generalized anxiety disease Diseases 0.000 title claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000012360 testing method Methods 0.000 description 31
- 230000000694 effects Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229920005439 Perspex® Polymers 0.000 description 5
- 230000001430 anti-depressive effect Effects 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 5
- 230000000949 anxiolytic effect Effects 0.000 description 5
- 229960001653 citalopram Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000004926 polymethyl methacrylate Substances 0.000 description 5
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 206010029333 Neurosis Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000015238 neurotic disease Diseases 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920004011 Macrolon® Polymers 0.000 description 1
- 239000004425 Makrolon Substances 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 238000001792 White test Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000002426 anti-panic effect Effects 0.000 description 1
- 230000000338 anxiogenic effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000002493 climbing effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199900991 | 1999-07-08 | ||
| PCT/DK2000/000377 WO2001003694A1 (fr) | 1999-07-08 | 2000-07-07 | Traitement de troubles nevrotiques |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20020062D0 NO20020062D0 (no) | 2002-01-07 |
| NO20020062L NO20020062L (no) | 2002-01-07 |
| NO329021B1 true NO329021B1 (no) | 2010-07-26 |
Family
ID=8099796
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20020062A NO329021B1 (no) | 1999-07-08 | 2002-01-07 | Anvendelse av escitalopram for behandling av generell angstforstyrrelse |
| NO20100333A NO20100333L (no) | 1999-07-08 | 2010-03-10 | Behandling av nevrotiske forstyrrelser |
| NO20100335A NO20100335L (no) | 1999-07-08 | 2010-03-10 | Behandling av nevrotiske forstyrrelser |
| NO20100334A NO20100334L (no) | 1999-07-08 | 2010-03-10 | Behandling av nevrotiske forstyrrelser |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20100333A NO20100333L (no) | 1999-07-08 | 2010-03-10 | Behandling av nevrotiske forstyrrelser |
| NO20100335A NO20100335L (no) | 1999-07-08 | 2010-03-10 | Behandling av nevrotiske forstyrrelser |
| NO20100334A NO20100334L (no) | 1999-07-08 | 2010-03-10 | Behandling av nevrotiske forstyrrelser |
Country Status (38)
| Country | Link |
|---|---|
| US (6) | US7271194B2 (fr) |
| EP (4) | EP1440691A3 (fr) |
| JP (1) | JP4773011B2 (fr) |
| KR (1) | KR100604176B1 (fr) |
| CN (1) | CN1198610C (fr) |
| AR (1) | AR021155A1 (fr) |
| AT (1) | ATE339955T1 (fr) |
| AU (6) | AU782514B2 (fr) |
| BG (4) | BG106279A (fr) |
| BR (1) | BR0011578A (fr) |
| CA (4) | CA2687394A1 (fr) |
| CL (3) | CL2008003941A1 (fr) |
| CO (1) | CO5190674A1 (fr) |
| CY (1) | CY1105806T1 (fr) |
| CZ (1) | CZ200270A3 (fr) |
| DE (1) | DE60030861T2 (fr) |
| DK (1) | DK1200081T3 (fr) |
| EA (1) | EA006555B1 (fr) |
| ES (1) | ES2272298T3 (fr) |
| HK (1) | HK1048069B (fr) |
| HR (1) | HRP20010820A2 (fr) |
| HU (1) | HUP0201791A3 (fr) |
| IL (5) | IL146131A0 (fr) |
| IS (1) | IS6137A (fr) |
| ME (2) | MEP2508A (fr) |
| MX (1) | MXPA01011626A (fr) |
| MY (1) | MY143278A (fr) |
| NO (4) | NO329021B1 (fr) |
| PL (1) | PL352030A1 (fr) |
| PT (1) | PT1200081E (fr) |
| SI (1) | SI1200081T1 (fr) |
| SK (1) | SK82002A3 (fr) |
| TR (4) | TR200402276T2 (fr) |
| TW (1) | TWI232101B (fr) |
| UA (1) | UA77645C2 (fr) |
| WO (1) | WO2001003694A1 (fr) |
| YU (1) | YU78701A (fr) |
| ZA (1) | ZA200108856B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| GB0005477D0 (en) | 2000-03-07 | 2000-04-26 | Resolution Chemicals Limited | Process for the preparation of citalopram |
| EP1301502B1 (fr) | 2000-07-21 | 2005-05-18 | H. Lundbeck A/S | Composes et leur utilisation comme inhibiteurs du transport de glycine |
| CN1509169A (zh) * | 2001-05-01 | 2004-06-30 | H��¡�±�������˾ | 对映体纯艾司西酞普兰的用途 |
| JP2005525993A (ja) | 2001-07-31 | 2005-09-02 | ハー・ルンドベック・アクチエゼルスカベット | エスシタロプラムを含む結晶性組成物 |
| US20040067963A1 (en) * | 2002-07-08 | 2004-04-08 | University Of Florida | Methods to prevent or ameliorate trauma-related psychological disorders |
| ATE388947T1 (de) * | 2002-12-23 | 2008-03-15 | Lundbeck & Co As H | Escitalopramhydrobromid und ein verfahren zu dessen herstellung |
| US20050137255A1 (en) * | 2002-12-23 | 2005-06-23 | H. Lundbeck A/S | Crystalline escitalopram hydrobromide and methods for preparing the same |
| TR200504022T1 (tr) * | 2003-03-24 | 2006-08-21 | Hetero Drugs Limited | (S)-sitalopram oksalatın yeni sıvı kristal formları. |
| US20090093461A1 (en) * | 2003-07-02 | 2009-04-09 | Astrazeneca Ab | Methods of Treating Anxiety and Mood Disorders |
| US7855195B2 (en) * | 2003-12-02 | 2010-12-21 | Pharmaneuroboost N.V. | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US8304431B2 (en) * | 2003-12-02 | 2012-11-06 | Pharmaneuroboost N.V. | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US7884096B2 (en) * | 2003-12-02 | 2011-02-08 | Pharmaneuroboost N.V. | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| JP2009511606A (ja) | 2005-10-14 | 2009-03-19 | ハー・ルンドベック・アクチエゼルスカベット | エスシタロプラムおよびブプロピオンの低用量の併用を用いる中枢神経系障害の治療方法 |
| US20070134322A1 (en) * | 2005-12-14 | 2007-06-14 | Forest Laboratories, Inc. | Modified and pulsatile release pharmaceutical formulations of escitalopram |
| FR2912057B1 (fr) * | 2007-02-07 | 2009-04-17 | Sanofi Aventis Sa | Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine |
| TW200817003A (en) * | 2006-07-31 | 2008-04-16 | Sanofi Aventis | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1143702A (fr) | 1965-03-18 | |||
| GB1526331A (en) | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| US4439545A (en) | 1981-11-19 | 1984-03-27 | Societe D "Expansion Scientifique "Expansia" | Acrylic copolymers of N-acryloylpolymethyleneimines or N-acryloyldialkylamides, N,N'-acryloyldiaminoalcanes and N-acryloylaminoacids (or esters) their preparation and use as cation exchangers |
| GB8419963D0 (en) | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
| GB8607313D0 (en) * | 1986-03-25 | 1986-04-30 | Ici Plc | Pharmaceutical compositions |
| GB8814057D0 (en) | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| US4902710A (en) | 1988-12-14 | 1990-02-20 | Eli Lilly And Company | Serotonin and norepinephrine uptake inhibitors |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US4962128A (en) | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
| US5296507A (en) * | 1990-09-06 | 1994-03-22 | H.Lundbeck A/S | Treatment of cerbrovascular disorders |
| DK213290D0 (da) | 1990-09-06 | 1990-09-06 | Lundbeck & Co As H | Treatment of cerebrovascular disorders |
| US5708035A (en) | 1991-02-04 | 1998-01-13 | Sepracor Inc. | Methods of use and compositions of R(-) fluoxetine |
| AU1919592A (en) | 1991-04-16 | 1992-11-17 | National Institutes Of Health | Method of treating trichotillomania and onychophagia |
| EP0612242B1 (fr) | 1991-11-15 | 2003-07-09 | Sepracor Inc. | Utilisation de l' isomere s(+) pur de fluoxetine pour la preparation d'un medicament contre la migraine |
| EP0714663A3 (fr) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A |
| US5627196A (en) * | 1995-01-17 | 1997-05-06 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| AU4918796A (en) * | 1995-02-10 | 1996-08-27 | Eli Lilly And Company | Methods of treating or preventing psychiatric disorders |
| US5554383A (en) | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
| SE9501567D0 (sv) | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
| EP0759299B1 (fr) | 1995-08-16 | 2000-04-26 | Eli Lilly And Company | Potentialisation de la sérotonine |
| US5846982A (en) * | 1996-06-14 | 1998-12-08 | Eli Lilly And Company | Inhibition of serotonin reuptake |
| US5912256A (en) * | 1996-06-20 | 1999-06-15 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| US5747494A (en) * | 1996-06-28 | 1998-05-05 | U C B S.A. | Pharmaceutical compositions for the treatment of depressive disorders |
| US5958429A (en) | 1996-08-16 | 1999-09-28 | Eli Lilly And Company | Potentiation of serotonin response |
| ZA977967B (en) | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| US5776969A (en) * | 1997-02-27 | 1998-07-07 | Eli Lilly And Company | Treatment of sleep disorders |
| US6069177A (en) | 1997-07-08 | 2000-05-30 | The Hong Kong University Of Science And Technology | 3-Hydroxy-propanamine derived neuronal reuptake inhibitors |
| SE9703379D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | New compounds |
| SE9703375D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
| SK283907B6 (sk) * | 1997-11-11 | 2004-04-06 | H. Lundbeck A/S | Spôsob výroby citalopramu a medziprodukty |
| EP0957099B1 (fr) * | 1998-04-15 | 2002-11-20 | Pfizer Products Inc. | Carboxamides hétérocycliques |
| EP1100501A4 (fr) * | 1998-06-30 | 2002-12-04 | Lilly Co Eli | Pyrrolidine et derives de pyrrolidine influen ant les systemes associes a la serotonine |
| EP1096926B1 (fr) | 1998-07-13 | 2007-02-28 | Nps Pharmaceuticals, Inc. | Procedes et composes permettant de traiter la depression |
| US6579899B1 (en) | 1998-07-16 | 2003-06-17 | Massachusetts Institute Of Technology | Composition for treatment of stress |
| WO2000003701A1 (fr) | 1998-07-16 | 2000-01-27 | Massachusetts Institute Of Technology | Composition pour le traitement du stress |
| US6150376A (en) * | 1998-08-05 | 2000-11-21 | Georgetown University | Bi- and tri-cyclic aza compounds and their uses |
| SE9803158D0 (sv) * | 1998-09-16 | 1998-09-16 | Astra Ab | A new composition |
| SE9803157D0 (sv) | 1998-09-16 | 1998-09-16 | Astra Ab | A new composition |
| BR9915158B1 (pt) * | 1998-10-20 | 2012-02-22 | método para preparação de citalopram, e, compostos da fórmula geral viii, ix e iv, ou qualquer de seus enantiÈmeros e sais com adição de ácido do mesmo. | |
| AR021509A1 (es) * | 1998-12-08 | 2002-07-24 | Lundbeck & Co As H | Derivados de benzofurano, su preparacion y uso |
| CZ296537B6 (cs) * | 1999-04-14 | 2006-04-12 | H. Lundbeck A/S | Zpusob výroby citalopramu a meziprodukty |
| AR021155A1 (es) | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| US6333357B1 (en) | 1999-11-05 | 2001-12-25 | Be Able, Llc | Behavior chemotherapy |
| UA77650C2 (en) | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
| WO2001080845A2 (fr) | 2000-04-24 | 2001-11-01 | Aryx Therapeutics | Substances et méthodes de traitement de la dépression |
| JP2002361405A (ja) * | 2000-09-25 | 2002-12-18 | Showa Denko Kk | 熱交換器の製造方法 |
| CN1509169A (zh) * | 2001-05-01 | 2004-06-30 | H��¡�±�������˾ | 对映体纯艾司西酞普兰的用途 |
-
2000
- 2000-07-06 AR ARP000103442A patent/AR021155A1/es unknown
- 2000-07-07 TR TR2004/02276T patent/TR200402276T2/xx unknown
- 2000-07-07 TR TR2004/02275T patent/TR200402275T2/xx unknown
- 2000-07-07 EP EP04007522A patent/EP1440691A3/fr not_active Withdrawn
- 2000-07-07 WO PCT/DK2000/000377 patent/WO2001003694A1/fr active Application Filing
- 2000-07-07 PT PT00943692T patent/PT1200081E/pt unknown
- 2000-07-07 KR KR1020017016006A patent/KR100604176B1/ko not_active IP Right Cessation
- 2000-07-07 AT AT00943692T patent/ATE339955T1/de active
- 2000-07-07 IL IL14613100A patent/IL146131A0/xx unknown
- 2000-07-07 CA CA2687394A patent/CA2687394A1/fr not_active Abandoned
- 2000-07-07 DK DK00943692T patent/DK1200081T3/da active
- 2000-07-07 TR TR2004/02277T patent/TR200402277T2/xx unknown
- 2000-07-07 CA CA2687392A patent/CA2687392A1/fr not_active Abandoned
- 2000-07-07 EP EP04007520A patent/EP1440689A3/fr not_active Withdrawn
- 2000-07-07 EP EP04007521A patent/EP1440690A3/fr not_active Withdrawn
- 2000-07-07 EP EP00943692A patent/EP1200081B1/fr not_active Revoked
- 2000-07-07 ME MEP-25/08A patent/MEP2508A/xx unknown
- 2000-07-07 SI SI200030910T patent/SI1200081T1/sl unknown
- 2000-07-07 MX MXPA01011626A patent/MXPA01011626A/es not_active Application Discontinuation
- 2000-07-07 PL PL00352030A patent/PL352030A1/xx not_active Application Discontinuation
- 2000-07-07 SK SK8-2002A patent/SK82002A3/sk not_active Application Discontinuation
- 2000-07-07 TR TR2002/00014T patent/TR200200014T2/xx unknown
- 2000-07-07 CA CA2687396A patent/CA2687396A1/fr not_active Abandoned
- 2000-07-07 CN CNB008100292A patent/CN1198610C/zh not_active Expired - Lifetime
- 2000-07-07 JP JP2001508974A patent/JP4773011B2/ja not_active Expired - Lifetime
- 2000-07-07 MY MYPI20003122A patent/MY143278A/en unknown
- 2000-07-07 UA UA2001128286A patent/UA77645C2/uk unknown
- 2000-07-07 ME MEP-2008-25A patent/ME00032B/fr unknown
- 2000-07-07 ES ES00943692T patent/ES2272298T3/es not_active Expired - Lifetime
- 2000-07-07 CO CO00051031A patent/CO5190674A1/es not_active Application Discontinuation
- 2000-07-07 CA CA002373757A patent/CA2373757C/fr not_active Expired - Lifetime
- 2000-07-07 YU YU78701A patent/YU78701A/sh unknown
- 2000-07-07 HU HU0201791A patent/HUP0201791A3/hu unknown
- 2000-07-07 CZ CZ200270A patent/CZ200270A3/cs unknown
- 2000-07-07 BR BR0011578-9A patent/BR0011578A/pt active Search and Examination
- 2000-07-07 EA EA200200137A patent/EA006555B1/ru not_active IP Right Cessation
- 2000-07-07 AU AU58061/00A patent/AU782514B2/en not_active Expired
- 2000-07-07 DE DE60030861T patent/DE60030861T2/de not_active Expired - Lifetime
- 2000-07-28 TW TW089115110A patent/TWI232101B/zh not_active IP Right Cessation
-
2001
- 2001-10-23 IL IL146131A patent/IL146131A/en active IP Right Grant
- 2001-10-26 ZA ZA200108856A patent/ZA200108856B/xx unknown
- 2001-10-30 IS IS6137A patent/IS6137A/is unknown
- 2001-11-06 HR HR20010820A patent/HRP20010820A2/hr not_active Application Discontinuation
- 2001-12-12 US US10/021,126 patent/US7271194B2/en not_active Expired - Lifetime
-
2002
- 2002-01-04 BG BG106279A patent/BG106279A/bg unknown
- 2002-01-04 BG BG11046809A patent/BG110468A/bg unknown
- 2002-01-04 BG BG11046609A patent/BG110466A/bg unknown
- 2002-01-04 BG BG11046709A patent/BG110467A/bg unknown
- 2002-01-07 NO NO20020062A patent/NO329021B1/no not_active IP Right Cessation
-
2003
- 2003-01-09 HK HK03100231.6A patent/HK1048069B/zh not_active IP Right Cessation
- 2003-08-07 US US10/637,821 patent/US20040029957A1/en not_active Abandoned
- 2003-08-07 US US10/637,822 patent/US20040029958A1/en not_active Abandoned
- 2003-08-07 US US10/637,820 patent/US7265151B2/en not_active Expired - Lifetime
- 2003-08-20 US US10/644,143 patent/US6960613B2/en not_active Expired - Lifetime
-
2005
- 2005-06-20 AU AU2005202684A patent/AU2005202684B2/en not_active Ceased
- 2005-06-20 AU AU2005202685A patent/AU2005202685B2/en not_active Ceased
- 2005-06-20 AU AU2005202686A patent/AU2005202686B2/en not_active Expired
- 2005-08-09 IL IL170194A patent/IL170194A/en unknown
- 2005-08-09 IL IL170192A patent/IL170192A/en unknown
- 2005-08-09 IL IL170193A patent/IL170193A/en unknown
-
2006
- 2006-11-27 CY CY20061101706T patent/CY1105806T1/el unknown
-
2007
- 2007-08-10 US US11/837,317 patent/US20070276035A1/en not_active Abandoned
-
2008
- 2008-12-24 AU AU2008264182A patent/AU2008264182A1/en not_active Withdrawn
- 2008-12-24 AU AU2008264188A patent/AU2008264188A1/en not_active Withdrawn
- 2008-12-30 CL CL2008003941A patent/CL2008003941A1/es unknown
- 2008-12-30 CL CL2008003938A patent/CL2008003938A1/es unknown
- 2008-12-30 CL CL2008003939A patent/CL2008003939A1/es unknown
-
2010
- 2010-03-10 NO NO20100333A patent/NO20100333L/no not_active Application Discontinuation
- 2010-03-10 NO NO20100335A patent/NO20100335L/no not_active Application Discontinuation
- 2010-03-10 NO NO20100334A patent/NO20100334L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005202685B2 (en) | Treatment of Neurotic disorders | |
| EA008373B1 (ru) | Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом | |
| EA008372B1 (ru) | Применение эсциталопрама для лечения расстройства, связанного с социальной тревогой |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104 |
|
| MK1K | Patent expired |